Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PYC Therapeutics has completed a time-course evaluation of incorporating its Cell Penetrating Peptide (CPP) technology in mice over four weeks
  • PYC is at the forefront of developing a revolutionary new class of drugs — delivering large drugs into cells
  • Based on results, there is potential to achieve an acceptable dosing regimen in humans when using PYC’s technology to treat blinding eye diseases

PYC Therapeutics has completed a time-course evaluation of the effectiveness of a drug incorporating its Cell Penetrating Peptide (CPP) technology in mice over four weeks.

The result has demonstrated the drug continues to achieve its desired effect throughout the full time period of the study.

PYC is at the forefront of developing a revolutionary new class of drugs — delivering large drugs into cells.

CPPs can overcome the “delivery” challenge and provide access for a wide range of potent and precise drug cargoes to the “undruggable genome” — the highest value drug targets that exist inside cells.

Based on the evaluation, PYC believes there’s potential to achieve an acceptable dosing regimen in humans when using PYC’s technology to treat blinding eye diseases.

Further to this, significant time intervals between drug administration can increase patient compliance levels, subsequently leading to better treatment outcomes.

The company is particularly pleased by the fact a low dose of drug was administered to achieve the positive result.

A single dose of 1.6 micrograms per eye was used in the study, which is approximately 60 times lower than the dose used in similar pre-clinical studies of “naked” Anti-Sense Oligonucleotides.

PYC owns the world’s largest and most structurally diverse library of natural peptides. The library contains billions of distinct peptides that represent a rich source of drug leads to target a broad range of diseases.

PYC by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…